Development of sulphonamide-trimethoprim combinations for urinary tract infections
Tóm tắt
Plasma levels and renal excretion of sulphonamide and trimethoprim following oral administration of co-trimazine (410 mg sulphadiazine + 90 mg trimethoprim) and co-trimoxazole (800 mg sulphamethoxazole + 180 mg trimethoprim) were monitored in healthy volunteers after a single dose and in the steady state after 12-hourly dosage. The plasma levels of free, non-protein bound components after co-trimazine were approximately half those after co-trimoxazole and thus correlated with the doses given. Urine recovery of trimethoprim was better after cotrimazine (70%) than after co-trimoxazole (58%). Sixty-six percent of the sulphadiazine was recovered as unchanged, active sulphonamide in the urine compared with only 13% of the sulphamethoxazole. Consequently, the sulphonamide levels of sulphadiazine were 2.5 times those of sulphamethoxazole. With respect to plasma half-life after the first dose, sulphadiazine with 8.0 hours was closer to trimethoprim with a half-life of 8.8 hours after cotrimazine and 9.6 hours after co-trimoxazole than to the half-life of sulphamethoxazole which was 7.7 hours. The distribution volume of sulphadiazine was closer to that of trimethoprim than was that of sulphamethoxazole. On the basis of these characteristics, it has been concluded that sulphadiazine is more suitable for a fixed combination tablet with trimethoprim than sulphamethoxazole, particularly for the treatment of urinary tract infections. Some renal tubular reabsorption occurs with both unchanged sulphonamides but is more pronounced with sulphamethoxazole. The solubilities of the sulphonamides and their acetylated metabolites at acid urinary pH indicate that therapy with co-trimazine is at least as safe as with co-trimoxazole. With the former drug, the result of scrutiny for crystals after dosage until the steady state was negative, whereas crystals of acetylated sulphamethoxazole were detected and verified chemically in two of eight subjects.
Tài liệu tham khảo
Böhni, E. Vergleichende Untersuchungen mit der Kombination Trimethoprim/Sulfamethoxazol in vitro und in vivo. Chemother. Suppl. 14 (1969) 1–21.
Böhni, E.: Sensitivity testing and outcome of therapy with the combination trimethoprim/sulphamethoxazole in patients with urinary tract infections. Proc. 6th Int. Congr. Chemother., Tokyo, 1970, pp. 975–980.
Küchler, R., Koch. V. J. The in vitro demonstration of the efficacy of trimethoprim as an antibacterial agent in a comparative bacteriological study on the effects of trimethoprim, sulphamethoxazole and the combination trimethoprim/sulphamethoxazole. Chemotherapy 18 (1973) 242–252.
Then, R. Influence of sulphonamide antagonists on the synergism of sulphamethoxazole/trimethoprim inEscherichia coli. Zbl. Bakt. I. Abt. Orig. 225 (1973) 34–41.
Alfthan, O. S., Liewendahl, K. Investigation of sulphonamide crystalluria in man. Scand. J. Urol. Nephrol. 6 (1972) 44–46.
Bergan, T., Brodwall, E. K. Human pharmacokinetics of a sulphamethoxazole-trimethoprim combination. Acta med. scand. 192 (1972) 483–492.
Bergan, T., Brodwall, E. K. Kidney transport in man of sulphamethoxazole and trimethoprim. Chemotherapy 17 (1972) 320–333.
Grüneberg, R. N., Kolbe, R. Trimethoprim in the treatment of urinary infections in hospital. Br. Med. J. I (1969) 545–547.
Hughes, D. T. D. Single-blind comparative trial of trimethoprim-sulphamethoxazole and ampicillin in the treatment of exacerbation of chronic bronchitis. Br. Med. J. IV (1969) 470–473.
Rieder, J., Schwartz, D. E., Fernex, M., Bergan, T., Brodwall, E. K., Blumberg, A., Cottier, P., Scheitlin, W. Pharmacokinetics of the antibacterial combination sulphamethoxazole plus trimethoprim in patients with normal or impaired kidney function. Antibiot. Chemother. 18 (1974) 148–198.
Schwartz, D. E., Rieder J. Pharmacokinetics of sulphamethoxazole + trimethoprim in man and their distribution in the rat. Chemotherapy 15 (1970) 337–355.
Rolinson, G. N., Sutherland, R. The binding of antibiotics to serum proteins. Br. J. Pharmacol. 25 (1965) 638–650.
Rieder, J. Quantitative demonstration of the bacteriostatically active fraction of sulphonamides and the sum of their inactive metabolites in the body fluids. Chemotherapy 17 (1972) 1–21.
Bratton, A. C., Marshall, E. K. A new coupling component for sulphanilamide determination. J. Biol. Chem. 128 (1939) 537–550.
Wagner, J. G. Fundamentals of clinical pharmacokinetics. Drug. Intelligence Publications, Hamilton/Ill., 1975.
Dettli, L. Dosierungstheorie für die repetierte Applikation reversibel wirkender Pharmaka bei Eliminationsinsuffizienz. In:Dengler, H. J. (eds.): Pharmacological and clinical significance of pharmacokinetics. Schattauer Verlag, Stuttgart/New York, 1970, pp. 31–41.
Dettli, L. Spring, P. Pharmacokinetics as a basic medical problem. In:Ariens, E. J. (eds.): Physicochemical Aspects of Drug Action. Third International Pharmacological Meeting. Vol. 7. Pergamon Press, Oxford, 1968, pp. 5–32.
Krüger-Thiemer, E. Bünger, P. The role of the therapeutic regimen in dosage design. Chemotherapia 10 (1965/66) 129–144.
Meyerson, B., Nordbring, F., Winberg. J.: Sulfonamider. Farmakologi, klink. Socialstyrelsens kommité för läkemedelsinformation. Stockholm, 1970, pp. 6–7.
Männistö, P., Tuomisto, J., Saris, N.-E., Lehtinen, T. Pharmacokinetic studies with trimethoprim and different doses of sulphadiazine in healthy human subjects. Chemotherapy 19 (1973) 289–298.
Ekström, B., Fellner, H., Forsgren, U., Magni, L., Örtengren, B. Antibacterial activity of co-trimazine in vitro and in vivo. Infection 7 (1979) 74–80.
Bergan, T., Øydvin, B. Cross-over study of infusions of penicillins. Chemotherapy. 20 (1974) 263–279.
Bünger, P., Diller, W., Führ, J., Krüger-Thiemer, E. Vergleichende Untersuchungen an neuerem Sulfanilamiden. 1. Mitteilung. Arzneim.-Forsch. 11 (1961) 247–255.
Struller, T. Progress in sulphonamide research. Progr. Drug. Res. 12 (1968) 389–457.
Tuomisto, J., Saris, N.-E. Effective plasma and urine concentrations. Ann. Med. Exp. Fenn. 18 (1970) 38–48.
Ohnhaus, E. E., Spring, P. Elimination kinetics of sulphadiazine in patients with normal and impaired renal function. J. Pharmacokinet. Biopharm. 3 (1975) 171–179.
Plummer, M. N., Wheeler, C. The toxicity of sulphadiazine. Observation on 1357 cases. Am. J. Med. Sci. 207 (1944) 175–184.
Lehr, D. Clinical toxicity of sulphonamides. Ann. N. Y. Acad. Sci. 69 (1957) 417–447.
Weinstein, L. The sulphonamides, In:Goodman, Gilman (eds.): The pharmacological basis of therapeutics. MacMillan, New York, 1970, pp. 1186–1203.